Seagate and SAB Biotherapeutics to Present at Major Investor Conferences in Early 2026

Seagate Technology and SAB Biotherapeutics have announced their participation in several high-profile investor conferences scheduled for the first quarter of 2026. SAB Biotherapeutics is set to attend the Guggenheim Securities Biotech Summit and the Oppenheimer Healthcare Life Sciences Conference this coming February. Simultaneously, Seagate Technology confirmed its presence at four major technology events throughout February and March, including conferences hosted by Morgan Stanley and Bernstein. The scheduled activities will feature fireside chats, one-on-one investor meetings, and webcasted presentations focused on corporate strategy and product pipelines. These events offer a platform for companies to engage with institutional investors and provide updates on key developments, such as SAB's type 1 diabetes treatment programs. While these conferences enhance corporate visibility, they are considered routine financial calendar events and typically have a neutral impact on stock prices unless new material guidance is issued.